Thank development details developments well joining CODX's the you, proud provide financial call. all relating Andrew. second results done regarding to Today, you quarter to testing. recent our a has quality goal earnings I’m are our Thank we excited of as our everyone. Good advance team affordable XXXX as life of best-in-class, of for product our through pipeline. better work to creating PCR afternoon,
PCR validate I to greatest Our sum discuss shortly, Co-Dx that the platform and recent new are exemplify which further on we in needs. grants, of Home will target unmet healthcare's our interest a serve
As for we patented be platform leveraging point-of-treatment a CoPrimer can has new tens been technology for to and the unique small, used platform, a of PCR device in is of cost clinical currently COVID-XX test are and the videos undergoing available is right of in develop deployed millions tests website. clinical home. Photos technology, our used our fraction PCR are at our centers, evaluations our that world of portable, will which variety and initial in available today. the to high-complexity reminder, assays which and labs a instrument and point-of-care on down around this conventional be sold of of The even
that helps AACC, Having a our conferences is this the valuable our as remain moving of at need our industry, and broad market Academy to of traffic world meeting, market of event or affordable visitors. in Clinical held high Anaheim and industry testing in end the interest to of Attended unmet the July. nearly Chemistry's and and XX,XXX around filling like direction annual for the an largest was PCR AACC participants and a gatherings one mission. cross-section progress technology of in awareness committed foot The booth the experienced professionals, the are at high reinforced levels healthcare diagnostics at we demand accurate showcasing confirm by provides presence to and of leaders from American
we as by well Co-Dx for in device. initial well, some activity, as going there, complete trials to and remain our recent regulatory discussed the also grant evaluations we schedule While on are These Home study clinical are our PCR the we submission end earnings of shared this in seeing. In that by was and we're funded previous a the early Gates analytical Foundation Bill by process. calls, & year, usability encouraged and with we PATH, them third-party Melinda data
data COVID-XX this assay to share to ease performance track the confirmed right new that was our on the for and the insightful the demonstrated bringing technology of happy further that use to study from and we lab-quality platform. setting. the are PCR we study complete, our are resulting Now of point-of-care The
potential details this that we in that help of parties to by recently awarded we been More our Co-Dx product. we Recall grants innovative multiple of us quarter, the PCR last quarter announced also grants advance the awarded. Home notable discussed have
which to and support our test that for and COVID-XX to that from $X.X detection B, development, the The RADx include the be believe will A of be grant COVID, is million flu RSV. products will our accelerate tests. what respiratory arm reach is to an we This first clinics is commercialization, will implementation Tech, and used and seeks first one point-of-care, at innovation of multiplex which NIH, for new
begin view test expect accelerate to Home COVID-XX greater commercialization, evaluations market even season. that will upcoming during we for the an the other first our opportunity device's the within multiplex flu diseases, indication clinical we this target market path the respiratory While PCR see still we to for as and
with from through version market and Home we reminder, to a another PCR multiplex base. aim meet the test new As along platform, distributor suitable this our both customers will laboratory that be to centralized demand
human that mortality crisis have rates. or infection which or World fallen global to awarded The of reduce addressing second Bill the to Organization significantly risen have Due platform, to by the and initiative, by papillomavirus, has and shift incidence World new TB were been world's global lack Two its the Gates Melinda off Health last and End in COVID, and to and TB, few support the two towards United Nations diseases The to and development & pandemic to track the high aims on have Foundation the third the TB infections Organization grants the HPV. TB testing committed of tests tuberculosis, access this addressing Health through since continue focus XXXX. meet goal, years. in TB
annual XX our undiagnosed accessible providing the Gates Organization. a from to recommendation reduce X TB new According TB million and/or incidence to accompanied by the more go million affordable of test, global the It estimated is and a cases Foundation, Health mission about by World unreported.
this XXXX. for test We expect begin to clinical in evaluations
ultimately, evaluating to most World are regulatory and these regulatory conduct and clearance, provide direct different criteria Health recommendation those We will by future using filings to believe the path studies Organization. that the jurisdictions the as we
providing greatest they on in and common which most the the develop third The to diagnostic to is to vaccine. updates on grant as award the will common of be world, the cervical is this therapeutic look test, new to for a cancer an one used forward used which HPV platform, HPV expected cancer, us in be the as is one most risk of project the factors help come. We fourth also a world. companion STIs
prestigious that by honored to testing. of quality by to providing have to grants are been diagnostic crucial We organizations seek improve these awarded access life
beyond Co-Dx supporters. assays As such The present advance the through process, insightful we approval a platform experienced the looks with and align ourselves are into and been regulatory as has future. we PCR our the designed pleased that and to platform Home
As keep front all cutting-edge or such, healthcare we trends. available are leveraging to intelligence, us, utilizing artificial to AI, of tools help in including
incorporated development. Co-Dx has now, our machine years into test several learning For CoPrimer's
to help more to make more tests make community as an we platform, robust effective, the monitoring of Now, ultimately able it analyze the for software AI predict track are that greater on need outbreaks possibly help and with leverage using the even to the are the the world and intend more deployed result de-identified test PCR better even powerful affected all further and aim more to to areas. otherwise for model are results, for than run software AI might the the overlooked, and control devices the the of before. of trends healthcare in our been future, as being have platform's component we training in data around and And, CO-Dx outlier gradually power Home to resources
focused Lastly, end platform, here have The scale. on ramping for our our we for We Co-Diagnostics products. of Lake aptly that manufacturing been to up scheduled upon facility by right meet install to a new is be ensures our this leased of is end-market manufacture City that year. operational instruments manufacturing plant Currently, in space commercial capacity. in Salt XX to new anticipation of the demand the assays will will and at of lines launch new the that this be prepared demand plan construction new
to venture of to around low needs intend other joint in the countries that our world. utilize service the India, available also to and Cosara the and Diagnostics, manufacturing us capacity through We and diagnostic resources help country middle-income
pivot needs. of a more testing a in to exciting as Co-Dx lab with the at There the never our to has greatest expand we time places been walls beyond enable strategy
well capacity for moving early data, us development interest, and market new position Our strong partnerships, clinical trial very all forward. expansion
we expect the to market to toward global to seek strong progress make we our As excited distribution a mix, witness share you updating leveraging we to win existing product and look company will our and I'm milestones. progress continued forward branding. as further the diversified advance by footprint that
turn our With will financials to second that, greater to Brian? in over I detail. quarter discuss the Brian call
